A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852)

P. H. Thaker, R. Salani, W. E. Brady, H. A. Lankes, D. E. Cohn, D. G. Mutch, R. S. Mannel, K. M. Bell-McGuinn, P. A. Di Silvestro, D. Jelovac, J. S. Carter, W. Duan, K. E. Resnick, D. S. Dizon, C. Aghajanian, P. M. Fracasso

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Preclinical studies demonstrate poly(ADP-ribose) polymerase (PARP) inhibition augments apoptotic response and sensitizes cervical cancer cells to the effects of cisplatin. Given the use of cisplatin and paclitaxel as first-line treatment for persistent or recurrent cervical cancer, we aimed to estimate the maximum tolerated dose (MTD) of the PARP inhibitor veliparib when added to chemotherapy. Patients and methods: Women with persistent or recurrent cervical carcinoma not amenable to curative therapy were enrolled. Patients had to have received concurrent chemotherapy and radiation as well as possible consolidation chemotherapy; have adequate organ function. The trial utilized a standard 3+3 phase I dose escalation with patients receiving paclitaxel 175mg/m2 on day 1, cisplatin 50mg/m2 on day 2, and escalating doses of veliparib ranging from 50 to 400mg orally two times daily on days 1-7. Cycles occurred every 21 days until progression. Dose-limiting toxicities (DLTs) were assessed at first cycle. Fanconi anemia complementation group D2 (FANCD2) foci was evaluated in tissue specimens as a biomarker of response. Results: Thirty-four patients received treatment. DLTs (n=1) were a grade 4 dyspnea, a grade 3 neutropenia lasting≥3 weeks, and febrile neutropenia. At 400mg dose level (DL), one of the six patients had a DLT, so the MTD was not reached. Across DLs, the objective response rate (RR) for 29 patients with measurable disease was 34% [95% confidence interval (CI), 20%-53%]; at 400mg DL, the RR was 60% (n=3/5; 95% CI, 23%-88%). Median progression-free survival was 6.2 months (95% CI, 2.9-10.1), and overall survival was 14.5 months (95% CI, 8.2-19.4). FANCD2 foci was negative or heterogeneous in 31% of patients and present in 69%. Objective RR were not associated with FANCD2 foci (P=0.53). Conclusions: Combining veliparib with paclitaxel and cisplatin as first-line treatment for persistent or recurrent cervical cancer patients is safe and feasible.

Original languageEnglish (US)
Pages (from-to)505-511
Number of pages7
JournalAnnals of Oncology
Volume28
Issue number3
DOIs
StatePublished - Mar 2017

Keywords

  • Cervical cancer
  • Novel therapeutics
  • PARP inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852)'. Together they form a unique fingerprint.

Cite this